Modified Directly Observed Therapy for Improving Antiretroviral Therapy Adherence in People With HIV

Not Applicable

Completed

• Conditions: HIV Infections
• Interventions: Behavioral: Modified Directly Observed Therapy; Behavioral: Standard Care

• Registration Number: NCT00339092
• Lead Sponsor: Massachusetts General Hospital

Brief Summary

This study will evaluate the effectiveness of a modified directly observed therapy program in increasing antiretroviral therapy adherence in poor, HIV-infected residents of urban communities.

Detailed Description

Antiretroviral drug therapy (ART) is a type of medication treatment for HIV that impairs the virus's ability to multiply. When used properly, it has been shown to be successful in reducing HIV-related deaths. A 95% adherence rate to ART is required to adequately suppress the virus and prevent transmission. High rates of mental illness, substance use, and unstable housing, however, make adherence to ART particularly problematic in poor urban populations. Directly observed therapy (DOT), in which medication intake is closely monitored, improved treatment adherence during the tuberculosis epidemic of the 1990s, and is now gaining recognition as a model for improving ART adherence. HIV DOT has been successfully delivered to people residing in structured living settings. The majority of HIV-infected people, however, live outside these facilities. Therefore, there is a need for a modified version of DOT to reach HIV-infected people in community settings. This study will evaluate the effectiveness of a MDOT program in increasing ART adherence in poor, HIV-infected residents of urban communities.

Participants in this open label study will be randomly assigned to either receive standard care or participate in the MDOT program. Participants assigned to standard care will report to the study site once a month for 9 months, but will not receive any assistance with taking HIV medications. Information about medication adherence, housing, income, use of health services, drug use, sexual practices, and mental health services will be collected at each visit. Participants in the MDOT program will report to the study site each morning for 3 months, Monday through Friday, to take their HIV medication and any other medications prescribed by their primary care doctors. If an individual does not attend a visit, study staff will try to locate the individual in the neighborhood to deliver the medication. Medication for the weekend will be prepared by study staff, but participants will take it on their own at home. At the end of 3 months, participants will no longer attend the study site for medication assistance. They will, however, participate in Action Point, a county program that helps participants adhere to taking medication, for an additional 3 months. Participants will also check in with the study staff once a month. Following this, participants may choose to discontinue the Action Point program for the final 3 months of the study. They will continue monthly check-in visits with the study staff. At each visit, interviews will be conducted and medication adherence will be assessed. Blood tests will be performed once every 3 months throughout the study.

Study Timeline

• Study Start: 2003-01
• Study First Submitted: 2006-06-16
• Study First Submitted QC: 2006-06-16
• Study First Posted: 2006-06-20
• Primary Completion: 2008-04
• Study Completion: 2008-04
• Status Verified: 2013-04
• Last Update Submitted: 2013-04-17
• Last Update Posted: 2013-04-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• HIV infected
• Severely immunosuppressed (HIV viral load of greater than 400 copies/ml)
• Does not consistently take prescribed ARV
• Currently prescribed HIV medications or prescribed to start taking HIV medications

Exclusion Criteria

• Currently participating in any other adherence program or intervention study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Treatment	Modified Directly Observed Therapy	Participants who receive storefront modified directly observed therapy (MDOT) of prescribed antiretrovirals
Control	Standard Care	Participants who receive standard care

Primary Outcome Measures

Name	Time	Method
CD4 and Viral Load	Measured at baseline and Months 3, 6, and 9

Secondary Outcome Measures

Name	Time	Method
Adherence	Measured monthly for 9 months

Trial Locations

Locations (1)

UCSF Market Street Study Site; 🇺🇸 San Francisco, California, United States